Poseida Therapeutics, Inc. (PSTX)の価格はいくらですか

Poseida Therapeutics, Inc. (PSTX)の価格は$9.50です

Poseida Therapeutics, Inc. (PSTX)の時価総額は何ですか

Poseida Therapeutics, Inc. (PSTX)の時価総額は$819.52Mです

Poseida Therapeutics, Inc.（PSTX）配当利回り

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

年	配当利回り	変化
2026 (TTM)	0.00%	0.00%
2023	0.00%	0.00%
2022	0.00%	0.00%
2021	0.00%	0.00%
2020	0.00%	0.00%
2019	0.00%	0.00%
2018	0.00%	0.00%
2017	0.00%	0.00%
2016	0.00%	0.00%

年

配当利回り

変化

2026 (TTM)

0.00%

0.00%

2023

0.00%

0.00%

2022

0.00%

0.00%

2021

0.00%

0.00%

2020

0.00%

0.00%

2019

0.00%

0.00%

2018

0.00%

0.00%

2017

0.00%

0.00%

2016

0.00%

0.00%

企業	配当利回り	国
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

企業

配当利回り

国